A limited exception of cancer‐induced tolerance is seen in CD169 (Siglec1 or sialoadhesin)‐positive macrophages (Gunnarsdottir et al., 2023) that cross‐present cancer antigens (Grabowska et al., 2018; Reis‐Sobreiro et al., 2021). Here, SIGLEC1 is linked to cancer.